- Home
- IHS vs MESO Comparison
IHS vs MESO Comparison
Compare IHS & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHS
- MESO
- Stock Information
- Founded
- IHS 2001
- MESO 2004
- Country
- IHS United Kingdom
- MESO Australia
- Employees
- IHS N/A
- MESO N/A
- Industry
- IHS Telecommunications Equipment
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IHS Telecommunications
- MESO Health Care
- Exchange
- IHS Nasdaq
- MESO Nasdaq
- Market Cap
- IHS 979.2M
- MESO 1.1B
- IPO Year
- IHS 2021
- MESO N/A
- Fundamental
- Price
- IHS $2.74
- MESO $10.18
- Analyst Decision
- IHS Strong Buy
- MESO Strong Buy
- Analyst Count
- IHS 7
- MESO 4
- Target Price
- IHS $9.07
- MESO $11.50
- AVG Volume (30 Days)
- IHS 342.3K
- MESO 214.1K
- Earning Date
- IHS 11-12-2024
- MESO 08-28-2024
- Dividend Yield
- IHS N/A
- MESO N/A
- EPS Growth
- IHS N/A
- MESO N/A
- EPS
- IHS N/A
- MESO N/A
- Revenue
- IHS $1,783,187,000.00
- MESO $5,902,000.00
- Revenue This Year
- IHS N/A
- MESO $66.05
- Revenue Next Year
- IHS $2.40
- MESO $348.27
- P/E Ratio
- IHS N/A
- MESO N/A
- Revenue Growth
- IHS N/A
- MESO N/A
- 52 Week Low
- IHS $2.18
- MESO $1.61
- 52 Week High
- IHS $5.28
- MESO $12.18
- Technical
- Relative Strength Index (RSI)
- IHS 45.82
- MESO 54.47
- Support Level
- IHS $2.53
- MESO $10.00
- Resistance Level
- IHS $2.94
- MESO $10.98
- Average True Range (ATR)
- IHS 0.16
- MESO 0.59
- MACD
- IHS 0.01
- MESO 0.05
- Stochastic Oscillator
- IHS 62.07
- MESO 46.61
About IHS IHS Holding Limited
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, most of who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.